Use Of Mevidalen And Other D1 Positive Allosteric Modulators In The

Use Of Mevidalen And Other D1 Positive Allosteric Modulators In The Treatment Of Hallucinations And Dementia Related Psychosis

Abstract: The present invention relates to methods of treating and dosing regimens using Mevidalen, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3- hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone, and/or pharmaceutical compositions thereof, for treatment of hallucinations and/or psychosis, including dementia-related psychosis.

Patent Information

Application #

Filing Date

05 October 2023

Publication Number

36/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ELI LILLY AND COMPANY

Lilly Corporate Center Indianapolis, IN 46285

Inventors

1. BIGLAN, Kevin, Michael

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288

2. SVENSSON, Kjell, Anders, Ivan

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288

Specification

Documents

Application Documents

#	Name	Date
1	202317066687-STATEMENT OF UNDERTAKING (FORM 3) [05-10-2023(online)].pdf	2023-10-05
2	202317066687-REQUEST FOR EXAMINATION (FORM-18) [05-10-2023(online)].pdf	2023-10-05
3	202317066687-POWER OF AUTHORITY [05-10-2023(online)].pdf	2023-10-05
4	202317066687-FORM 18 [05-10-2023(online)].pdf	2023-10-05
5	202317066687-FORM 1 [05-10-2023(online)].pdf	2023-10-05
6	202317066687-FIGURE OF ABSTRACT [05-10-2023(online)].pdf	2023-10-05
7	202317066687-DRAWINGS [05-10-2023(online)].pdf	2023-10-05
8	202317066687-DECLARATION OF INVENTORSHIP (FORM 5) [05-10-2023(online)].pdf	2023-10-05
9	202317066687-COMPLETE SPECIFICATION [05-10-2023(online)].pdf	2023-10-05
10	202317066687-Proof of Right [17-10-2023(online)].pdf	2023-10-17
11	202317066687-FORM 3 [05-04-2024(online)].pdf	2024-04-05